온코크로스, 온코마스터 흡수합병…AI 회사서 데이터로 플랫폼 축 이동

Oncocross's acquisition of Oncomaster signals an industry-wide recognition that AI oncology solutions require validated patient data to achieve commercial viability—shifting focus from algorithmic innovation alone to data-driven precision medicine platforms. By acquiring a 10,000-patient cancer cohort, the company aims to strengthen biomarker discovery, drug targeting, and diagnostic capabilities through real-world clinical evidence. The critical test will be whether Oncocross can monetize this data asset through collaborative research and diagnostic services fast enough to meet its 2027 profitability target.